ESC Heart Failure (Aug 2021)

Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism

  • Payman Zamani,
  • Elizabeth A. Proto,
  • Neil Wilson,
  • Hossein Fazelinia,
  • Hua Ding,
  • Lynn A. Spruce,
  • Antonio Davila Jr.,
  • Thomas C. Hanff,
  • Jeremy A. Mazurek,
  • Stuart B. Prenner,
  • Benoit Desjardins,
  • Kenneth B. Margulies,
  • Daniel P. Kelly,
  • Zoltan Arany,
  • Paschalis‐Thomas Doulias,
  • John W. Elrod,
  • Mitchell E. Allen,
  • Shana E. McCormack,
  • Gayatri Maria Schur,
  • Kevin D'Aquilla,
  • Dushyant Kumar,
  • Deepa Thakuri,
  • Karthik Prabhakaran,
  • Michael C. Langham,
  • David C. Poole,
  • Steven H. Seeholzer,
  • Ravinder Reddy,
  • Harry Ischiropoulos,
  • Julio A. Chirinos

DOI
https://doi.org/10.1002/ehf2.13329
Journal volume & issue
Vol. 8, no. 4
pp. 2698 – 2712

Abstract

Read online

Abstract Aims Skeletal muscle (SkM) abnormalities may impact exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF). We sought to quantify differences in SkM oxidative phosphorylation capacity (OxPhos), fibre composition, and the SkM proteome between HFpEF, hypertensive (HTN), and healthy participants. Methods and results Fifty‐nine subjects (20 healthy, 19 HTN, and 20 HFpEF) performed a maximal‐effort cardiopulmonary exercise test to define peak oxygen consumption (VO2, peak), ventilatory threshold (VT), and VO2 efficiency (ratio of total work performed to O2 consumed). SkM OxPhos was assessed using Creatine Chemical‐Exchange Saturation Transfer (CrCEST, n = 51), which quantifies unphosphorylated Cr, before and after plantar flexion exercise. The half‐time of Cr recovery (t1/2, Cr) was taken as a metric of in vivo SkM OxPhos. In a subset of subjects (healthy = 13, HTN = 9, and HFpEF = 12), percutaneous biopsy of the vastus lateralis was performed for myofibre typing, mitochondrial morphology, and proteomic and phosphoproteomic analysis. HFpEF subjects demonstrated lower VO2,peak, VT, and VO2 efficiency than either control group (all P < 0.05). The t1/2, Cr was significantly longer in HFpEF (P = 0.005), indicative of impaired SkM OxPhos, and correlated with cycle ergometry exercise parameters. HFpEF SkM contained fewer Type I myofibres (P = 0.003). Proteomic analyses demonstrated (a) reduced levels of proteins related to OxPhos that correlated with exercise capacity and (b) reduced ERK signalling in HFpEF. Conclusions Heart failure with preserved ejection fraction patients demonstrate impaired functional capacity and SkM OxPhos. Reductions in the proportions of Type I myofibres, proteins required for OxPhos, and altered phosphorylation signalling in the SkM may contribute to exercise intolerance in HFpEF.

Keywords